Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Streamlined development, evaluation, and clinical translation of radiopharmaceuticals requires a partner with extensive scientific, regulatory, and operational expertise. Choosing a reliable imaging provider offering a complete solution ensures your critical data is delivered in a timely manner to make a go/no-go decision on your imaging or therapeutic candidates.
Perceptive has played a critical role in the radioligand therapy (RLT) space, having supported over 80 RLT clinical trials and hundreds of preclinical studies targeting a multitude of therapeutic indications and targets.
We collaborate with 85% of RLT companies on the market, keeping our finger firmly on the pulse of this rapidly evolving field. As pioneers in RLT, we have played a critical role in developing and registering PSMA-targeted therapies in the context of metastatic castration-resistant prostate cancer and have supported more novel targets such as fibroblast activation protein.
Learn why you can rely on Perceptive’s extensive radiopharmaceutical experience, including:
Stay on top of industry trends and learn how Perceptive is helping sponsors and CROs design and implement clinical trials effectively – and efficiently.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
